We are live on
!
Find out more
WP
Woodline Partners Portfolio holdings
AUM
$26.4B
1-Year Est. Return
44.85%
This Fund
S&P 500
This Quarter
Est. Return
+6.33%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
–
AUM
$3.05B
AUM Growth
+$527M
(+21%)
Cap. Flow
+$482M
Cap. Flow
% of AUM
15.81%
Top 10 Holdings %
Top 10 Hldgs %
28.17%
Holding
230
New
83
Increased
48
Reduced
47
Closed
52
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microchip Technology
MCHP
|
+$73.6M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$66.4M |
| 3 |
Amazon
AMZN
|
+$65.7M |
| 4 |
Johnson & Johnson
JNJ
|
+$61.2M |
| 5 |
Mastercard
MA
|
+$61M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Intel
INTC
|
+$65M |
| 2 |
PayPal
PYPL
|
+$52M |
| 3 |
eBay
EBAY
|
+$48.4M |
| 4 |
NXP Semiconductors
NXPI
|
+$42.9M |
| 5 |
Qorvo
QRVO
|
+$42M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 44.94% |
| 2 | Technology | 31.58% |
| 3 | Communication Services | 6.58% |
| 4 | Consumer Discretionary | 4.22% |
| 5 | Financials | 3.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
JNCE
101
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $7.59M | 0.25% |
+929,651
| New | +$5.76M |
|
102
Regenxbio
RGNX
$659M
| $7.58M | 0.25% |
275,442
+133,731
| +94% | +$4.36M |
|
|
GLUU
103
DELISTED
Glu Mobile Inc.
GLUU
| $7.47M | 0.24% |
+973,123
| New | +$8.17M |
|
|
AKUS
104
DELISTED
Akouos Inc
AKUS
| $7.45M | 0.24% |
325,831
+6,818
| +2% | +$152K |
|
105
PMV Pharmaceuticals
PMVP
$59.7M
| $7.36M | 0.24% |
+207,421
| New | +$7.63M |
|
106
Wolfspeed
WOLF
$1.27B
| $7.32M | 0.24% |
+114,780
| New | +$7.43M |
|
107
Avnet
AVT
$7.29B
| $7.25M | 0.24% |
280,596
+120,138
| +75% | +$3.26M |
|
|
LEAP.U
108
DELISTED
Ribbit LEAP, Ltd. Units, each consisting of one Class A Ordinary Share, and one fifth of one Warrant
LEAP.U
| $6.71M | 0.22% |
+516,400
| New | +$6.58M |
|
|
IGMS
109
DELISTED
IGM Biosciences
IGMS
| $6.67M | 0.22% |
+90,378
| New | +$5.35M |
|
110
Iovance Biotherapeutics
IOVA
$1.95B
| $6.54M | 0.21% |
+198,684
| New | +$6.09M |
|
111
Silicon Laboratories
SLAB
$7.19B
| $6.32M | 0.21% |
64,581
+13,659
| +27% | +$1.37M |
|
112
Outset Medical
OM
$92.5M
| $6.28M | 0.21% |
+8,372
| New | +$6.88M |
|
113
American Well
AMWL
$180M
| $6.27M | 0.21% |
+10,583
| New | +$5.58M |
|
|
INFN
114
DELISTED
Infinera Corporation Common Stock
INFN
| $6.17M | 0.2% |
1,001,608
+913,554
| +1,037% | +$6.39M |
|
115
Annexon
ANNX
$860M
| $6.07M | 0.2% |
+200,738
| New | +$4.71M |
|
|
ATNX
116
DELISTED
Athenex, Inc. Common Stock
ATNX
| $6.05M | 0.2% |
+25,000
| New | +$6M |
|
|
SYNH
117
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $6.01M | 0.2% |
+113,119
| New | +$6.74M |
|
118
AMN Healthcare
AMN
$1.28B
| $5.95M | 0.19% |
101,744
-147,193
| -59% | -$7.75M |
|
|
CHMA
119
DELISTED
Chiasma, Inc. Common Stock
CHMA
| $5.71M | 0.19% |
1,328,257
+908,521
| +216% | +$4.35M |
|
120
Ciena
CIEN
$55.3B
| $5.54M | 0.18% |
+139,676
| New | +$7.35M |
|
|
CVET
121
DELISTED
Covetrus, Inc. Common Stock
CVET
| $5.52M | 0.18% |
+226,378
| New | +$4.88M |
|
122
Prelude Therapeutics
PRLD
$350M
| $5.4M | 0.18% |
+179,361
| New | +$5.07M |
|
123
Dyne Therapeutics
DYN
$4.71B
| $5.39M | 0.18% |
+266,799
| New | +$5.85M |
|
124
Kymera Therapeutics
KYMR
$8.25B
| $5.37M | 0.18% |
+166,217
| New | +$5.07M |
|
125
TG Therapeutics
TGTX
$7.07B
| $5.35M | 0.18% |
199,875
-132,777
| -40% | -$3.06M |
|
Similar funds
PAM
TCIIS
UIM
VAI
Woodline Partners's Q3 2020 Portfolio in Review
As of Q3 2020, Woodline Partners held 230 positions worth $3.05B, up 21% from $2.52B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Woodline Partners deployed $482M of net new capital in Q3 2020, opening 83 new positions and adding to 48 existing holdings. Its largest new stake was Microchip Technology: 1,413,308 shares worth $72.6M.
By sector, the portfolio is most concentrated in Healthcare at 45% of assets, down from 47% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Intel, an estimated $65M trimmed.
- Woodline Partners's largest Q3 2020 buy was Microchip Technology: 1,413,308 shares worth $72.6M.
- Woodline Partners added most to Johnson & Johnson in Q3 2020, an estimated $61.2M increase.
- Woodline Partners's biggest Q3 2020 reduction was Intel, cutting an estimated $65M.
- Woodline Partners fully exited PayPal in Q3 2020, selling an estimated $52M.
- Woodline Partners's ten largest holdings make up 28% of its $3.05B portfolio in Q3 2020.
- Woodline Partners opened 83 new positions and closed 52 in Q3 2020.
- Woodline Partners's portfolio value rose 21% quarter-over-quarter to $3.05B.
Based on Woodline Partners's 13F filing for Q3 2020, filed 16 Nov 2020.